share_log

Exicure | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

Exicure | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

Exicure | NT 10-Q:季報延遲披露公告
美股sec公告 ·  05/15 16:52
Moomoo AI 已提取核心訊息
Exicure, Inc. has announced that it will not meet the prescribed due date for filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024. The delay is due to the company's ongoing process of completing restatements for its financial statements for the first and second quarters of 2023, as well as the filing of related Form 10-Q amendments and its third quarter of 2023 financial statements. Additionally, Exicure needs to complete and file its Annual Report on Form 10-K for the year ended December 31, 2023. The company has not filed its third quarter 2023 10-Q and 2023 10-K reports. Significant changes in operations are anticipated in the upcoming earnings statements due to a major reduction in workforce, suspension of preclinical activities, and...Show More
Exicure, Inc. has announced that it will not meet the prescribed due date for filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024. The delay is due to the company's ongoing process of completing restatements for its financial statements for the first and second quarters of 2023, as well as the filing of related Form 10-Q amendments and its third quarter of 2023 financial statements. Additionally, Exicure needs to complete and file its Annual Report on Form 10-K for the year ended December 31, 2023. The company has not filed its third quarter 2023 10-Q and 2023 10-K reports. Significant changes in operations are anticipated in the upcoming earnings statements due to a major reduction in workforce, suspension of preclinical activities, and cessation of all research and development activities announced in September 2022. Exicure is also exploring strategic alternatives to maximize shareholder value. As a result of these changes, there are no research and development expenses reported for 2024, and general and administrative expenses are expected to be lower than the previous year. The notification was signed by CEO Paul Kang on May 15, 2024.
Exicure, Inc.宣佈,它不會在規定的截止日期之前提交截至2024年3月31日的10-Q表季度報告。延遲是由於該公司正在完成2023年第一和第二季度的財務報表重報,以及相關的10-Q表修正案和2023年第三季度財務報表的提交。此外,Exicure需要填寫並提交截至2023年12月31日止年度的10-K表年度報告。該公司尚未提交其2023年第三季度10季度和2023年10-K報告。由於員工隊伍大幅裁員、暫停臨床前活動以及2022年9月宣佈停止所有研發活動,預計即將發佈的收益報表中將出現重大運營變化。Exicure還在探索戰略替代方案,以最大限度地提高股東價值。由於這些變化,沒有報告2024年的研發費用,一般和管理費用預計將低於上一年。該通知由首席執行官保羅·康於2024年5月15日簽署。
Exicure, Inc.宣佈,它不會在規定的截止日期之前提交截至2024年3月31日的10-Q表季度報告。延遲是由於該公司正在完成2023年第一和第二季度的財務報表重報,以及相關的10-Q表修正案和2023年第三季度財務報表的提交。此外,Exicure需要填寫並提交截至2023年12月31日止年度的10-K表年度報告。該公司尚未提交其2023年第三季度10季度和2023年10-K報告。由於員工隊伍大幅裁員、暫停臨床前活動以及2022年9月宣佈停止所有研發活動,預計即將發佈的收益報表中將出現重大運營變化。Exicure還在探索戰略替代方案,以最大限度地提高股東價值。由於這些變化,沒有報告2024年的研發費用,一般和管理費用預計將低於上一年。該通知由首席執行官保羅·康於2024年5月15日簽署。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息